Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Anti-interleukin-2 receptor alpha for multiple sclerosis?

Saidha S, Calabresi PA.

Lancet. 2013 Jun 22;381(9884):2141-3. doi: 10.1016/S0140-6736(13)60065-3. Epub 2013 Apr 4. No abstract available.

PMID:
23562008
2.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G; SELECT study investigators..

Lancet. 2013 Jun 22;381(9884):2167-75. doi: 10.1016/S0140-6736(12)62190-4. Epub 2013 Apr 4.

PMID:
23562009
3.

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.

Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG.

Neurology. 2007 Aug 21;69(8):785-9.

PMID:
17709711
4.

Daclizumab in treatment of multiple sclerosis patients.

Ali EN, Healy BC, Stazzone LA, Brown BA, Weiner HL, Khoury SJ.

Mult Scler. 2009 Feb;15(2):272-4. doi: 10.1177/1352458508097468. Epub 2009 Jan 9.

PMID:
19136546
5.

Journal club: Intrathecal effects of daclizumab treatment of multiple sclerosis.

Schneider R, Arbour N.

Neurology. 2012 May 29;78(22):e131-3. doi: 10.1212/WNL.0b013e31825830e3. No abstract available.

PMID:
22641406
6.

Daclizumab (Zinbryta) for multiple sclerosis.

[No authors listed]

Med Lett Drugs Ther. 2016 Sep 12;58(1503):117-9. No abstract available.

PMID:
27603962
7.

Ocrelizumab in multiple sclerosis: risks and benefits.

Chaudhuri A.

Lancet. 2012 Mar 31;379(9822):1196-7; author reply 1197. doi: 10.1016/S0140-6736(12)60508-X. No abstract available.

PMID:
22464382
8.

Multiple sclerosis-quenching the flames of inflammation.

Chataway J, Miller DH.

Lancet. 2011 Nov 19;378(9805):1759-60. doi: 10.1016/S0140-6736(11)61133-1. Epub 2011 Oct 31. No abstract available.

PMID:
22047970
9.

Phase III clinical trial using daclizumab for relapsing-remitting multiple sclerosis initiated.

[No authors listed]

Immunotherapy. 2010 Jul;2(4):437. doi: 10.2217/imt.10.50. No abstract available.

10.

Daclizumab in multiple sclerosis: a high-yield extension study.

Barkhof F, Ciccarelli O.

Lancet Neurol. 2014 May;13(5):443-4. doi: 10.1016/S1474-4422(14)70056-0. Epub 2014 Mar 19. No abstract available.

PMID:
24656610
11.

Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.

Martin R.

Clin Immunol. 2012 Jan;142(1):9-14. doi: 10.1016/j.clim.2011.10.008. Epub 2011 Nov 9. Review.

PMID:
22284868
12.

Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.

Perumal JS, Foo F, Cook P, Khan O.

Mult Scler. 2012 Aug;18(8):1197-9. doi: 10.1177/1352458511435716. Epub 2012 Jan 17.

PMID:
22252465
13.

Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.

Hradilek P, Zeman D, Tudik I, Zapletalova O, Ulmann V.

Mult Scler. 2014 Apr;20(5):639-40. doi: 10.1177/1352458513501572. Epub 2013 Aug 19. No abstract available.

PMID:
23959714
14.

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.

Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL.

Lancet. 2011 Nov 19;378(9805):1779-87. doi: 10.1016/S0140-6736(11)61649-8. Epub 2011 Oct 31.

PMID:
22047971
15.

Alemtuzumab for multiple sclerosis: who and when to treat?

Sprenger T, Kappos L.

Lancet. 2012 Nov 24;380(9856):1795-7. doi: 10.1016/S0140-6736(12)61859-5. Epub 2012 Nov 2. No abstract available.

PMID:
23128041
16.

[2012: Update on diagnosis and treatment of multiple sclerosis].

Havla J, Kümpfel T, Hohlfeld R.

Dtsch Med Wochenschr. 2012 Apr;137(17):894-9. doi: 10.1055/s-0032-1304927. Epub 2012 Apr 10. Review. German. No abstract available. Erratum in: Dtsch Med Wochenschr. 2012 May;137(20):1072.

PMID:
22492476
17.

Lethal multiple sclerosis relapse after natalizumab withdrawal.

Rigau V, Mania A, Béfort P, Carlander B, Jonquet O, Lassmann H, Camu W, Thouvenot E.

Neurology. 2012 Nov 27;79(22):2214-6. doi: 10.1212/WNL.0b013e318275979d. Epub 2012 Oct 24. No abstract available.

PMID:
23100404
18.

An update on new and emerging therapies for relapsing-remitting multiple sclerosis.

Weinstock-Guttman B.

Am J Manag Care. 2013 Nov;19(17 Suppl):s343-54. Review.

19.

Alemtuzumab and the value of neurological research.

Lancet Neurology..

Lancet Neurol. 2014 Mar;13(3):233. doi: 10.1016/S1474-4422(14)70032-8. Epub 2014 Feb 17. No abstract available.

PMID:
24556003
20.

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.

Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW; CHOICE investigators..

Lancet Neurol. 2010 Apr;9(4):381-90. doi: 10.1016/S1474-4422(10)70033-8. Epub 2010 Feb 15. Erratum in: Lancet Neurol. 2010 Aug;9(8):759. Wadinger, K [corrected to Wandinger, K].

PMID:
20163990

Supplemental Content

Support Center